Screening

Should I have genetic testing for hereditary breast and ovarian cancer if I have Ashkenazi Jewish heritage?

People of Ashkenazi Jewish heritage have a higher chance of carrying certain gene changes that increase the risk of breast and ovarian cancer. Here's what you need to know about genetic testing if this applies to you.

Published Updated Reading time 7 min By Jeen Health editorial team
A woman discussing genetic testing options with a healthcare professional

If you have Ashkenazi Jewish heritage, you may have heard that your chance of carrying certain gene changes linked to cancer is higher than in the general population. This is true - and it means genetic testing might be particularly relevant for you, even if you don’t have a strong family history of cancer.

Why Ashkenazi Jewish heritage matters for cancer risk

People with Ashkenazi Jewish ancestry (families originating from Central or Eastern Europe) have a higher chance of carrying particular changes in the BRCA1 and BRCA2 genes. These genes normally help protect against certain cancers, but when they contain a pathogenic variant (a harmful change), the risk of developing breast, ovarian, and some other cancers increases substantially.

Three specific BRCA variants - known as founder mutations - are much more common in the Ashkenazi Jewish population than in the general population. This is due to what geneticists call a ‘founder effect’: the variants became more frequent because they were present in a small ancestral population. NHS England states that about 1 in 40 Ashkenazi Jewish people carry a faulty BRCA gene, compared with around 1 in 250 of the UK general population.

Most cancers develop due to a combination of factors including age, lifestyle, and chance. However, up to 10% of all cancers are related to an inherited genetic mutation that runs in families. Among people of Ashkenazi Jewish heritage, the proportion linked to these inherited BRCA variants is higher than in other populations.

What does carrying a BRCA variant mean for cancer risk?

Carrying a pathogenic variant in BRCA1 or BRCA2 does not mean you will definitely develop cancer - it means your risk is higher than average. This is because the ‘penetrance’ of these variants is incomplete: penetrance is the proportion of people with a variant who go on to develop the condition.

For women carrying a BRCA1 or BRCA2 variant:

For men carrying a BRCA variant:

BRCA1 and BRCA2 are not the only genes that matter. Multigene panel testing can identify pathogenic variants in other genes with high or moderate penetrance for breast cancer, such as PALB2, CHEK2, and ATM. These genes are included in comprehensive hereditary cancer screening.

Who should consider genetic testing?

Genetic testing is most useful when:

The NHS offers genetic testing and counselling if you meet certain criteria, which generally include a significant personal or family history of cancer. NHS England has also run a BRCA testing programme for adults aged 18 or over in England who have at least one Jewish grandparent, whether or not there is a family history of cancer. At the time of writing (October 2026) the programme is closed to new registrations, so check nhsjewishbrcaprogramme.org.uk for current availability before you pay for private testing. If you don’t meet NHS criteria but still want testing, or want a wider panel of genes, private testing is an option.

What happens during genetic testing?

Genetic testing involves:

  1. Pre-test counselling - a specialist genetic counsellor or clinician explains what the test looks for, what results might mean, and how they could affect you and your family. This is an essential part of the process and is included in every Jeen test.
  2. Providing a sample - usually a blood sample or a cheek swab (buccal swab). At-home cheek-swab kits are available for many tests.
  3. Laboratory analysis - your DNA is examined for pathogenic variants in the genes on the panel. This typically takes a few weeks.
  4. Results and follow-up - you receive your results with an explanation of what they mean, and guidance on what to do next.

There are three possible outcomes:

What can you do if you test positive?

If testing identifies a pathogenic variant, several options can help reduce your cancer risk or detect cancer early:

Knowing you carry a pathogenic variant can also guide cancer treatment if you do develop cancer. For example, BRCA-related cancers may respond to particular therapies that wouldn’t be used otherwise.

What you can do at Jeen

Jeen offers several genetic testing options for hereditary cancer risk, all with specialist genetic counselling included:

The NHS offers genetic testing when you meet specific clinical criteria, typically involving a significant personal or family cancer history. NHS England has also run a BRCA testing programme for adults with at least one Jewish grandparent; see nhsjewishbrcaprogramme.org.uk for current availability. Jeen’s panels offer a private route, with genetic counselling included - useful if you want a wider panel of genes or are not eligible for NHS testing.

Sources & further reading

  1. PubMed Patel MM, Adrada BE. Hereditary Breast Cancer: BRCA Mutations and Beyond. Radiol Clin North Am. 2024 DOI: 10.1016/j.rcl.2023.12.014. Accessed 18 September 2026.
  2. PubMed Pensabene M, Calabrese A, von Arx C, et al. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology. Cancer Treat Rev. 2024 DOI: 10.1016/j.ctrv.2024.102702. Accessed 18 September 2026.
  3. PubMed Van Cott C. Cancer Genetics. Surg Clin North Am. 2020 DOI: 10.1016/j.suc.2020.02.012. Accessed 18 September 2026.
  4. NHS NHS. Causes of breast cancer in women (inherited BRCA genes and NHS testing for people with a Jewish grandparent) Accessed 20 October 2026.
  5. NHS NHS England. Hundreds of people at increased cancer risk identified by new NHS BRCA testing programme Accessed 20 October 2026.
  6. Other Breast Cancer Now. Genetic testing for altered breast cancer genes Accessed 20 October 2026.
  7. Other NHS Jewish BRCA Testing Programme Accessed 20 October 2026.
ashkenazi-jewishbreast-cancerovarian-cancerbrca1brca2hereditary-cancer